Citations 1
Pemetrexed (Pem)/gemcitabine (Gem) as front-line therapy for advanced NSCLC: A randomized, phase II trial of three schedules
Adjei, Alex A. , Nair, S., Reuter, Nicholas F., Mandrekar, Sumithra J. , Kuross, Steven A., Rowland, K. M., Steen, Preston D. , Hillman, Shauna L., Jett, James R., Nair, S., Schild, Steven E.
Journal of Clinical Oncology | April 5, 2017 | Volume: 22 | Issue: 14_suppl | Pages: 7070-7070
